News Epizyme eyes lucrative use for newly-launched Tazverik US biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the FDA agreed to a fast review in follicular lymphoma.
Oncology Liver cancer diagnostic gets FDA breakthrough status, with P... Mursla Bio CEO and founder Pierre Arséne discusses the breakthrough designation from the FDA for their blood test to catch liver cancer early.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face